Bamlanivimab is administered intravenously and acts to help block the SARS-CoV-2 virus. The aim is to lessen the patient’s severe symptoms and avoid hospitalization.
Norton Healthcare is making monoclonal antibody treatment Bamlanivimab available under the Food and Drug Administration’s emergency use authorization for certain patients at high risk for requiring hospitalization for COVID-19. We are fortunate to have extensive expertise in the development and utilization of monoclonal antibodies in the treatment of a wide array of diseases.
Bamlanivimab is administered intravenously and acts to help block the SARS-CoV-2 virus. The aim is to lessen the patient’s severe symptoms and avoid a hospitalization. This is an investigational treatment requiring a provider order to administer.
Refer a patient
Use EpicLink to quickly and easily refer a patient to Norton Healthcare.
Make a referral
Bamlanivimab is for the treatment of mild to moderate COVID-19 in adults and pediatric patients age 12 and over. Patients must weigh at least 40 kilograms (88.2 pounds) with a positive SARS-CoV-2 viral test and be at high risk for progressing to severe COVID-19 or requiring hospitalization.
High risk is defined as patients who meet at least one of the following criteria:
- A body mass index (BMI) of at least 35
- Chronic kidney disease
- Immunosuppressive disease
- Currently receiving immunosuppressive treatment
- At least 65 years of age
- At least 55 years of age and have:
- Cardiovascular disease or hypertension
- Chronic obstructive pulmonary disease/other chronic respiratory disease
- Age 12 to 17 years of age AND have
- BMI greater than or equal to the 85th percentile for their age and gender based on Centers for Disease Control and Prevention growth charts
- Sickle cell disease
- Congenital or acquired heart disease
- Neurodevelopmental disorders, for example, cerebral palsy
- A medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)
- Asthma, reactive airway or other chronic respiratory disease that requires daily medication for control
Treatments for patients 18 years and older will be given at the Norton Infusion Centers at Norton Cancer Institute – Brownsboro and Norton Cancer Institute – Downtown.